智通财经APP获悉，丹麦制药巨头诺和诺德(NVO.US)与人工智能生物科技公司Valo Health周三宣布扩大合作，旨在加速心脏代谢疾病新疗法的研发。根据最新协议，双方将共同推进20个新药项目，涵盖心血管疾病、肥胖症和2型糖尿病，Valo有望获得总计约46亿美元的里程碑付款及其他研发资金和特许权使用费。
最初于2023年达成的合作协议聚焦于心血管疾病领域，诺和诺德与Valo同意共同推进多达11个药物项目。当时，Valo就有权获得高达27亿美元的里程碑付款。此次修订后的协议显著扩展了合作范围，新增了9个项目，专注于肥胖症、2型糖尿病和心血管疾病等治疗。
作为协议的一部分，Valo还将从诺和诺德获得1.9亿美元的综合资金，这包括预付款、股权投资以及潜在的近期里程碑付款。
诺和诺德科学主管Marcus Schindler对双方合作首年的进展表示高度满意，并强调了对扩大合作范围、关注更多疾病领域的期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.